跳至主要内容
临床试验/NCT04441671
NCT04441671撤回2 期

Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)

Tampere University Hospital0 个研究点开始时间: 2020年12月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
主要终点
Concentration area under the curve 0-t of pyrophosphate

研究概览

简要总结

Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be provided for healthy controls and PXE-patients both fasting and with standard meal intake.

详细描述

Phase II oral capsulized disodium-PPi (Na2H2PPi) powder absorption study in subjects with PXE (n=8-12) will be done in the ward of Internal Medicine of Tampere University Hospital and University Medical Center Utrecht.

After a 10-hour fast at 8.00 a.m. 30 mg/kg (first day) and 50 mg/kg (second day) capsulized dose of PPi will be given with 2 dl water. At 12.00 a.m. another capsulized 30 mg/kg (first day) or 50 mg/kg (second day) single dose of PPi with a standard mixed meal (lunch) will be given with 2 dl water at the time when a subject starts eating.

Plasma and urine sampling include plasma and spot urine electrolytes, creatinine, and pyrophosphate. Plasma sampling will be done at 0, 15, 30, 60, 120 and 240 min after ingestion of PPi. Urine spot sample will be taken at 0 and 240 min after ingestion of PPi.

Physical activity is restricted. Side-effects will be recorded.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (>18 yrs)
  • clinically and genetically proven PXE
  • Body mass index (BMI) 18,5-34,9 kg/m2

排除标准

  • Special groups according to researchers' decision.
  • Pregnancy
  • No effective contraception in females in child-bearing age.

研究组 & 干预措施

Open label

Experimental

Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00

干预措施: Disodium Pyrophosphate (Drug)

结局指标

主要结局

Concentration area under the curve 0-t of pyrophosphate

时间窗: two days

Maximal concentration of pyrophosphate

时间窗: two days

Cmax

Timepoint of maximal pyrophosphate concentration

时间窗: two days

Tmax

次要结局

  • Concentration area under the curve 0-t of phosphate(two days)
  • Maximal concentration of phosphate(two days)
  • Timepoint of maximal phosphate concentration(two days)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Oral Pyrophosphate Absorption in PXE Disease | 临床试验